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Abstract
Introduction: We describe clinical features and prognostic fac-
tors of renal medullary carcinoma (RMC) by performing a pooled 
analysis of all reported cases since 1995.
Methods:  A systematic search was performed to identify all arti-
cles describing patients with medullary renal cancer until February 
2013. Survivals were estimated using Kaplan-Meier method with 
95% confidence intervals and compared across the groups using 
the log-rank test. The following factors were evaluated using the 
Cox proportional hazards model: association of extension of dis-
ease at diagnosis, response to therapy, and surgical treatment of 
primary tumour with overall. 
Results: A total 47 articles were selected; these described 165 
patients with RMC plus 1 from our centre. The median age was 
21 years and 98% of cases had the sickle cell trait. The mean 
size of the primary tumours was 6.0 cm, with an involvement of 
loco-regional lymph nodes in 71% of cases. The overall survival at 
diagnosis was 4.0 months in metastatic patients and 17.0 months in 
non-metastatic patients. Patients who received platinum-paclitaxel-
gemcitabine had longer control of the disease when compared to 
topoisomerase inhibitors or targeted therapies. The multivariate 
analysis confirmed that the advanced stage at diagnosis increased 
the risk of death of about threefold. 
Conclusion: RMC is a tumour with poorer prognosis; based on 
these results, platinum-based chemotherapy is the preferred sys-
temic treatment. Even if radical nephrectomy as an up-front strategy 
did not report a survival benefit, it may be considered to palliate 
local symptoms and to perform a correct diagnosis.
Introduction 
Renal medullary carcinoma (RMC) is a rapidly growing 
tumour of the renal medulla associated almost exclusively 
with the sickle-cell trait. This rare tumour was first described 
by Davis and colleagues in 1995; they reported 34 cases 
collected over 22 years at the Armed Forces Institute of 
Pathology.1 Over the next 5 years, only 15 more cases have 
been described.2
Patients affected by RMC are usually younger African-
Americans, with a median age of 22 and affected by sickle-
cell trait.3 The diagnosis is normally performed with his-
tological examination of the tumour, even if those could 
be anticipated considering the clinical characteristics of 
the patient and the radiological signs of a centrally located 
tumour with an infiltrative growth pattern, and the typical 
invasion of the renal sinus.4
Since the rarity of this tumour does not allow experimen-
tal clinical trials, the best surgical or medical approach to 
treat the disease remain anecdotal. Generally, these patients 
have a radical nephrectomy with chemotherapy in the case 
of metastatic disease, but the effect of surgery on general 
prognosis has never been investigated and the prognosis 
remains poor. 
We aim to describe the clinical features and prognos-
tic factors of RMC by performing a pooled analysis of all 
reported cases since 1995.
Methods
A systematic search using MEDLINE/PubMed was performed 
using the search terms: “medullary carcinoma AND kid-
ney” published from January 1995 to February 2013. We 
limited the search to all English articles and articles related 
to humans. We also used references from selected articles 
to find other relevant publications related to our search. 
When available, data were extracted to focus on following 
parameters: age, sex, presence and type of symptoms, stage 
of disease at diagnosis, sites of metastasis, disease-free sur-
vival (DFS), overall survival (OS), progression-free survival 
(PFS) type of treatment and its efficacy. All data were used 
to create a database for final analysis.
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Statistical analysis 
Baseline values were expressed as median and interquartile 
range (IQR), with baseline defined as the date of surgery or 
first diagnosis whenever surgery was not performed.
DFS was defined as the length of time after surgery during 
which no disease was found.  OS was defined as the time 
from surgery to death or last contact and PFS was defined 
as the time from the start of therapy to the progression of 
disease or the death for any cause. The DFS, PFS, and OS 
were estimated using Kaplan-Meier method with 95% con-
fidence intervals (CI) and compared across the groups using 
the log-rank test. 
The following factors were evaluated using the Cox pro-
portional hazards model: association of extension of disease 
at diagnosis, response to therapy, and surgical treatment of 
primary tumour with overall. Multivariable analyses were 
performed using a stepwise selection approach with a type 
I error of 0.05 for model entry and 0.10 for elimination.
Correlations between type of therapy used and clini-
cal benefit (defined as the sum of the partial and complete 
response with the stability of disease at radiological evalua-
tion) were evaluated by the non-parametric Spearman rank 
test (rs). Statistical signifance was set at p < 0.05. 
All statistical analyses were performed using the Predictive 
Analytics SoftWare (PASW, v19; IBM SPSS).
Results 
Initially, we retrieved 226 articles, among these 182 were 
immediately rejected because they were related to other 
subjects, reviews or preclinical experiences. Another 2 arti-
cles were found from the references of selected articles. A 
total of 47 articles were included in the final analysis. These 
articles described the clinical characteristics of 165 patients 
(Table 1), and 1 patient from our institution was added for 
a total of 166 patients (Fig. 1). 
Baseline characteristics 
The median age was 21 (IQR: 15–29.5), and 71% of cases 
were male. The African Americans and the Caucasian race 
were reported in 93% and 7% of the valuable cases, respec-
tively; whereas the sickle-cell trait was found in 97.7% of 
patients (Table 2).
The main symptoms at diagnosis, found in 67% of cases, 
were hematuria and pain. Weight loss was found in 23% 
of cases, whereas respiratory symptoms related to pleural 
effusion or bulky disease, nausea and/or vomiting and the 
detection of a renal mass were present in less than 10% of 
patients.
The mean size of the primary tumours at diagnosis was 
6.0 cm (IQR: 4.7–8.0), and the involvement of loco-regional 
lymph nodes was reported in 70.8% of cases. The diagnosis 
was performed in the advanced stage in 80.5% of cases and 
half of these had a tumour greater than 6 cm. Of the total 
cases, 71.3% and 31.3% of patients had almost one or two 
sites of metastasis at the diagnosis, respectively. The most 
frequent sites were subdiaphragmatic nodes, lungs, liver, 
and local relapse or contralateral kidney (Table 3). 
Treatments and survivals 
The median OS was 5.0 months (95% CI, 2.4–7.6); this 
was longer in non-metastatic patients compared to patients 
with advanced disease at diagnosis (17.0 vs. 4.0 months; 
p = 0.001) (Fig. 2, part A). A total of 83.5% of patients 
had nephrectomy or tumour embolization (1 case), and 
survival was better in those patients compared to who did 
not have the nephrectomy or tumour embolization (6.0 
vs 3.0 months; p = 0.037) (Fig. 2, part B). Among the 20 
patients who did not received nephrectomy, the diagno-
sis was performed by biopsy of the renal mass in 7 cases, 
by biopsy of supraclavicular node in 4 cases, by autopsy 
in 3 cases, by urinary cytology in 1 case; data were not 
available in the remaining cases. In non-metastatic patients 
after treatment of the primary tumour, the median DFS was 
8.0 months (95% CI, 2.7–13.2). A non-significant benefit for 
radical nephrectomy was found in metastatic patients (5.0 
vs. 2.0 months; p = 0.067). 
Information about medical treatments was available for 
55 cases and among these 48 received first-line chemo-
therapy and 6% a treatment with target agents or interferon 
(IFN). In patients who received chemotherapy, platinum-
based treatment was administered in 59% of cases (Table 4). 
226 articles
45 articles
47 articles
2 articles from 
other sources
138 other subjects
22 reviews
21 preclinical studies
1 written in Chinese
Fig. 1. Flow-chart of study selection.
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In metastatic patients at diagnosis, the median OS was 
10.0 months in patients who received any platinum-based 
chemotherapy for advanced disease compared to 5.0 months 
in patients who did not, but difference was not significant 
(p = 0.098). A positive correlation was found between the 
use of platinum-based regimens, and the clinical benefit at 
first-line treatment (rs = 0.49, p = 0.005); moreover, patients 
who achieved clinical benefit had better OS compared to 
those who did not (12.0 vs. 4.0 months; p = 0.010).
Patients who received the cisplatin, paclitaxel and gem-
citabine regimen (CPG) experienced  longer PFS (8.0 vs. 1.0; 
p = 0.028) and longer OS (12.0 vs. 7.0: p = 0.031) compared 
to patients who received topoisomerase inhibitors. Better 
survivals were reported in patients treated with CPG com-
pared to the MVAC regimen: 8.0 versus 1.0 months for PFS 
(p = 0.064) and 12.0 versus 4.0 months for OS (p = 0.058), 
respectively – this is clinically, although not statistically, 
significant. 
Prognostic factors 
We performed a univariate and multivariate analysis to test 
if baseline characteristics, such as age ≥20, sex, stage at 
diagnosis, nephrectomy, primary tumour extension, and 
metastatic stage at diagnosis, affected survival. Two factors 
were dependent prognostic factors at univariate analysis: 
nephrectomy and metastatic stage at diagnosis. The multi-
variate analysis only confirmed the independent prognos-
tic role of metastatic stage at diagnosis (hazard ratio 2.71, 
95% CI 1.42–5.16; p = 0.003) (Table 5).
Discussion
RMC is a rare tumour characterized by little data about its 
pathogenesis. Pathologically, the renal medulla is character-
ized by anoxia, hyperosmolarity and low pH that promote 
hemoglobin S polymerization and red blood cell sickling. 
Table 1. Studies included in the final analysis
Authors PubMed ID Cases
Adsay N.V. et al. 9500230 1
Assad L. et al. 15593260 3
Avery R.A. et al. 8646708 6
Bell M.D. et al. 16514612 1
Coogan C.L. et al. 9609653 3
Davis C.J. et al. 7528470 33
Diao B. et al. 20656278 1
Dimashkieh H. et al. 12653601 2
Ellen A. ronnen et al. 16549825 1
Ellis C.L. et al. 19526572 2
Friedrichs P. et al. 9120938 1
Gangireddy V.G. et al. 22409864 2
Gatalica Z. et al. 21733559 3
Hakimi A.A. et al. 18068443 9
Herring J.C. et al. 9146631 1
Jeanette D. Hoenig et al. 12013017 1
Johnson R.P. et al. 21048487 1
Kalyanpur A. et al. 9308460 1
Khabir A. et al. 16309940 1
Khan A. et al. 10930759 1
Larson D.M. et al. 9557262 1
leitao  V.A. et al. 16549825 1
Mathur S.C. et al. 11035600 1
Milhoua P.M. et al. 18631900 1
Muhammad A.B. et al. 2569460 1
Nava V.E. et al. 21915032 1
Neville A. et al. 17406914 1
Noguera-Irizarry  W.G. et al. 14528077 1
Pickhardt P.J. et al. 11222193 1
Pirich L.M. et al. 10029817 1
Qi J. et al. 11575652 1
Rao P. et al. 22301499 14
Rathmell W.K. et al. 18649931 3
Sathyamoorthy K. et al. 16691241 1
Selby D.M. et al. 10737506 1
Sherburne R. et al. 9474131 2
Simpson L. et al. 15879768 3
Stahlschmidt J. et al. 10573578 1
Strouse J. et al. 15602719 2
Swartz M.A. et al. 12475675 40
Vargas-Gonzalez R. et al. 14530815 1
Walsh A. et al. 20979179 1
Warren K.E. et al. 9925868 1
Watanabe I. et al. 17643096 7
Wesche W.A. et al. 9566287 1
Yang X.J. et al. 14983493 2
Total no. cases 165
Table 2. Clinical characteristics of the entire cohort and 
symptoms at diagnosis
No. patients 166
Male sex 70%
Median age (IQR) 21 years (range: 15–30)
Patients over 20 years old 53.3%
Race
Afro-American 93%
Caucasian 7%
Sickle cell trait 97.7%
Type of symptoms
Hematuria 67.6%
Pain 67.6%
Weight loss 23.5%
Mass 9.0%
Respiratory distress 8.8%
Nausea vomiting 6.9%
IQR: interquartile range. 
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At the same time, the red blood cell sickling could cause 
obstruction of blood vessels and tissue hypoxia resulting in 
renal infarction and nephrotic syndrome, and subsequently 
gross hematuria, papillary necrosis, inability to concentrate 
the urine and pyelonephritis.5,6 All these conditions wors-
ened the hypoxic state considering the trigger for neoplastic 
transformation.7
This hypoxic phase was demonstrated by the high level 
of immunohistochemical expression of vascular endothe-
lial growth factor (VEGF) and hypoxia-inducible factor (HIF) 
in RMC cells, suggesting a possible common pathogenesis 
with classical clear-cell renal carcinoma (RCC).7 Despite 
this evidence, the gene expression profile has evidenced a 
specific pattern of gene’s amplification or deletion among 
RMC and clear-cell or papillary RCC that indicated a distinc-
tive biology and probably the need for different modalities 
of treatment.8 
Stahlschmidt and colleagues reported several numerical 
and structural chromosome changes, including isochromo-
somes for 1q, 8q and 17q, translocation between chromo-
somes 10 and 16, and between chromosomes 9 and 22, and 
rearrangement of the chromosomes 22 at q11. Moreover, the 
fluorescence in situ hybridization (FISH) analysis reported 
the translocation 9:22 contained a bcr/abl rearrangement 
commonly seen in chronic myeloid leukemia.9 On the con-
trary, other authors did not report any genetic change in 
9 out of 10 cases and only loss of chromosome 22 was 
described in 1 case.7,8 
Radiologically, the RMC can be characterized by the 
extension in the renal sinus that can cause distortion of 
the renal collecting system on intravenous urography. The 
contrast-enhanced computed tomography and magnetic res-
onance imaging show an infiltrative growth pattern from the 
renal medulla toward the renal cortex laterally, and the renal 
pelvis and sinus medially. The tumour may cause overall 
expansion of the kidney, while maintaining the reniform 
contour. Its medullary origin can be difficult to appreciate in 
cases of large masses; when the tumour is centrally located, 
it is often associated with caliectasis without pelviectasis. 
After contrast administration, some heterogeneous areas can 
be seen due to necrotic and hemorrhagic areas. These can 
appear as signal void on T2-weighted images with longer 
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Table 3. Characteristics of primary tumour and extension 
of disease at diagnosis
Mean size 6.0 cm (range: 4.7–8.0)
IV stage at diagnosis 80.5%
N° of metastatic sites
>1 71.3%
>2 31.3%
Metastatic sites
Sub-diaphragmatic nodes 70.8%
Lung 47.8%
Liver 26.8%
Kidney/surgical site 13.3%
Adrenal gland 13.3%
Upper-diaphragmatic nodes 12.4%
Bone 12.4%
Peritoneum 7.1%
Pleural 5.3%
Fig. 2. Impact of metastatic stage at diagnosis on overall survival (A) and impact of radical nephrectomy on overall survival (B).
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echo times due to the susceptibility effect caused by prod-
ucts of hemorrhage.10,11 
The clinical role of angiogenesis as a possible target 
was recently discarded by a retrospective review about 30 
patients with RMC treated at 4 institutions in the United 
States between 2000 and 2010.12 Six of these patients 
received the anti-angiogenic agent alone as up-front thera-
py and none achieved a response; whereas, only 1 patient 
achieved a response with erlotinib and bevacizumab when 
used as second-line. On the other hand, a higher rate of 
responses in first- and second-line was obtained in patients 
treated with chemotherapy. 
Collecting all data reported in medical literature in the last 
18 years, we were able to report the largest dataset about 
this disease and analyze clinical and prognostic features. 
We were able to find that most patients were symptomatic 
at diagnosis and we confirmed their poorer survival, at a 
median OS of 4 months in metastatic patients and less than 
17 months in non-metastatic ones.
Moreover chemotherapy induced a positive response in 
patients and patients treated with platinum-based combina-
tions had an increase in PFS. These results should be con-
sidered in light of this rare disease and the consequent lack 
of data about its management in clinical practice.  
In the attempt to increase the activity of chemotherapy, 
several authors have investigated the role of topoisomerase-
II-α (TopoII-α) in RMC. TopoII-α is an enzyme involved in 
cell proliferation, DNA maintenance and repair; it is targeted 
by some agents, such as anthracyclines and etoposide.8,13 
Albadine and colleagues found that TopoII-α was overex-
pressed in 85% of RMC cases; moreover, these tumours were 
characterized by a high rate of proliferation and short sur-
vival.13 Interestingly, no TopoII-α amplification was detect-
ed by FISH in the same patients suggesting that potential 
mechanisms, other than gene amplification, are responsible 
for TopoII-α overexpression in RMC.13 This evidence limits 
the possibility to predict tumour cell’s sensibility to specific 
inhibitors.
In our review group, 52% of treated patients received 
first-line chemotherapy with a least one TopoII inhibitor as 
anthracyclines or etoposide with or without cisplatin. No 
survival benefit was found compared to triplets or other 
chemotherapy regimens. 
We were unable to report on the role of other prognostic 
factors, with the exclusion of the advanced stage at diag-
nosis. The data on the effect of nephrectomy on survival is 
marginal.
Another limitation of this paper is its retrospective nature. 
Data were extrapolate from published articles and not from 
patient charts. Patients were treated at different hospitals 
and different times for radiological and clinical evaluations. 
Finally, we did not achieve a high level of evidence due to 
the heterogeneity of the data. 
Conclusion
We describe the clinical and prognostic cahrateristics of 
the largest group of patients affected by RMC. Despite our 
results, more efforts are needed to better understand the 
biology of this disease and to improve treatment strategies.
Competing interests: The authors declare no competing financial or personal interests.
Table 4. Surgical and medical treatments received by 
analyzed patients
Treatments Patients, %
Nephrectomy 83.5%
Medical treatment 87.7%
First line 56 patients
Chemotherapy 89.3%
Target agents 8.9%
Immune treatments 1.8%
Type of chemotherapy
CPG 10.9%
MVAC 28.3%
Response 27 patients
CR+PR+SD 26.9%
PD 73.1%
Second line 15 patients
 Chemotherapy 100%
CPG: cisplatin, paclitaxel and gemcitabine regimen; methotrexate, vinblastine, doxorubicin, 
and cisplatin; CR: complete response; PR: partial response; SD: stable disease; PD: 
progressive disease.
Table 5. Univariate Cox analysis for overall survival in metastatic patients
Factors
Univariate Cox regression analysis Multivariate Cox regression analysis
HR (95% CI) p value HR (95% CI) p value
Age ≥20 years old 0.82 (0.54 – 1.24) 0.37
Sex (M/F) 0.96 (0.60 – 1.56) 0.88
Primary tumour <6 cm (Y/N) 0.55 (0.20 – 1.06) 0.07
Nephrectomy (Y/N) 0.59 (0.35 – 0.99) 0.048 0.60 (0.35 – 1.02) 0.061
Metastatic at diagnosis (Y/N) 2.57 (1.38 – 4.77) 0.003 2.71 (1.42 – 5.16) 0.003
HR: hazard ratio; CI: confidence interval; Y: yes; N: no; M: male; F: female. 
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